Edgewise Therapeutics Stock Surges to $48.41 on Sale of Muscular Dystrophy Unit

Edgewise Therapeutics Inc. reached an all-time high of $48.41 on September 17, 2026, as the company finalized the sale of its muscular dystrophy pipeline to Servier. The transaction, valued at up to $2.65 billion, included an upfront payment of $1.55 billion and potential milestone payments of up to $1.1 billion. The deal followed regulatory clearance and the retention of key employees to transition to Servier’s team. Trading at $48.31, the company’s market capitalization stood at $5.22 billion, reflecting a 208% one-year stock price increase, though actual returns over the same period were slightly higher at 227% according to InvestingPro data. The stock remains near its 52-week high, just 1% below the $48.40 peak observed earlier that day.